세계의 혈전증 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Thrombosis Drugs Market is presumed to reach the market size of nearly USD 58.9 BN by 2032 from USD 31.37 BN in 2023 with a CAGR of 7.25% under the study period 2024 - 2032.

Thrombosis drugs are medications used to prevent or treat thrombosis, which is the formation of blood clots. These drugs, including anticoagulants and antiplatelet agents, are essential in managing conditions like deep vein thrombosis and pulmonary embolism and preventing stroke in patients with certain cardiovascular diseases.

MARKET DYNAMICS

The thrombosis drugs market is driven by factors such as the increasing prevalence of thrombotic disorders, aging populations, and lifestyle-related risk factors such as obesity and sedentary behavior. Thrombosis drugs, including anticoagulants and antiplatelet agents, are essential in preventing and treating conditions like deep vein thrombosis, pulmonary embolism, and stroke. The rising prevalence of cardiovascular diseases and the need for effective thromboprophylaxis in surgical and medical settings contribute to market growth. Additionally, advancements in drug formulations and the development of novel anticoagulants with improved safety profiles stimulate market demand. The expanding awareness of thrombosis risk factors and the importance of early intervention further fuel the market. Regulatory support for thrombosis management and the introduction of direct oral anticoagulants (DOACs) contribute to the evolving landscape of thrombosis drug therapies. Moreover, ongoing research and development activities focused on personalized medicine and targeted therapies aim to enhance the efficacy and safety of thrombosis drugs, shaping the market's trajectory.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of thrombosis drugs. The growth and trends of thrombosis drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the thrombosis drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Factor Xa Inhibitor
• Low Molecular Weight Heparin
• P2Y12 Platelet Inhibitor
• Others

By Indication

• Pulmonary Embolism
• Atrial Fibrillation
• Deep Vein Thrombosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Thrombosis Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Thrombosis Drugs market include GSK plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH Pfizer, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . THROMBOSIS DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Factor Xa Inhibitor Historic and Forecast Sales by Regions
• 5.5 Low Molecular Weight Heparin Historic and Forecast Sales by Regions
• 5.6 P2Y12 Platelet Inhibitor Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY INDICATION

• 6.1 Overview by Indication
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Indication
• 6.4 Pulmonary Embolism Historic and Forecast Sales by Regions
• 6.5 Atrial Fibrillation Historic and Forecast Sales by Regions
• 6.6 Deep Vein Thrombosis Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL THROMBOSIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE THROMBOSIS DRUGS COMPANIES

• 9.1. Thrombosis Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF THROMBOSIS DRUGS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. GSK plc
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Baxter International Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Johnson & Johnson
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Sanofi
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Bristol-Myers Squibb Company
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. AstraZeneca plc
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. Bayer AG
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Aspen Pharmacare Holdings Limited
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Boehringer Ingelheim GmbH Pfizer Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies